HareshS.JhangianiMDMBA

Hematology • Fountain Valley, CA

Physician

Join to view full profile

Dr. Jhangiani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jhangiani's full profile

Already have an account?

Office
11180 Warner Ave
Ste 351
Fountain Valley, CA 92708
Phone+1 714-698-0300

Fax+1 714-698-0303

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1987 - 1988
Kaiser Permanente Southern California (Los Angeles)Fellowship, Hematology and Medical Oncology, 1985 - 1987
Kaiser Permanente Southern California (Los Angeles)Residency, Internal Medicine, 1983 - 1984
Charles R Drew UniversityResidency, Pediatrics, 1982 - 1983
Trinity Health Oakland/Wayne State UniversityResidency, Internal Medicine, 1981 - 1982
Trinity Health Oakland/Wayne State UniversityInternship, Transitional Year, 1980 - 1981
Topiwala National Medical CollegeClass of 1978

Certifications & Licensure

CA State Medical License 1982 - 2026
MI State Medical License 1982 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 1997

Clinical Trials

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
Completed
Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Start of enrollment: 2014 Apr 01
Recruiting
Phase 3
Rociletinib (CO-1686) USA Expanded Access Program
No longer available
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Start of enrollment: 2018 Jan 02
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Jonathan Afari, Tanya M Spektor, Carley Turner, Alexa Cohen, Alberto Bessudo
Experimental Hematology. 2022-10-01
10 citations
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak
Clinical Lymphoma, Myeloma & Leukemia. 2020-11-01
50 citations
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuz...
Sara A. Hurvitz, Florence Dalenc, Mario Campone, Ruth O'Regan, Vivianne C. G. Tjan-Heijnen
Breast Cancer Research and Treatment. 2013-10-08

Professional Memberships

American College of Physicians - ACP
Fellow
American Society of Clinical Oncology - ASCO
Member